Комбинированная гепатопротекторная фармакотерапия заболеваний печени

В клинической практике нередко используются одновременно несколько гепатопротективных средств в виде отдельных препаратов или фиксированных комбинаций, выпускаемых фармацевтической промышленностью. Комбинированное применение может обеспечивать как усиление того или иного фармакологического эффекта, так и расширение спектра гепатотропного действия. Наиболее часто в комбинациях изучаются и применяются эссенциальные фосфолипиды, глицирризиновая кислота, урсодезоксихолевая кислота, силибинин и S-аденозилметионин. В работе обсуждены патогенетические обоснования комбинированного использования гепатотропных лекарственных средств и проведен анализ результатов доклинических и клинических исследований, посвященных использованию комбинаций при различных заболеваниях печени.

заболевания печени, гепатопротекторы, эссенциальные фосфолипиды, глицирризиновая кислота, урсодезоксихолевая кислота, силибинин, S-аденозилметионин

1. Fong S.Y., Brandl M., Bauer-Brandl A. Phospholipid-based solid drug formulations for oral bioavailability enhancement: A meta-analysis. Eur J Pharm Sci. 2015;80:89-110. https://doi.org/10.1016/j.ejps.2015.08.005

2. Medvedeva N.V., Prosorovskiy V. N., Ignatov D. V., et al. Biomed Khim. 2015;61(2):219-230. (In Russ.) https://doi.org/10.18097/PBMC20156102219@@Медведева Н. В., Прозоровский В. Н., Игнатов Д. В. и др. Лекарственные препараты и транспортные наносистемы на основе растительных фосфолипидов. Биомедицинская химия. 2015;61(2):219-230. https://doi.org/10.18097/PBMC20156102219

3. Okovityi S.V., Bolotova V. Ts., Anisimova N. A., et al. Prospects for using plant extracts to correct fat and carbohydrate metabolism disorders. Pharmacy. 2020;69(2):17-22. (In Russ.) https://doi.org/10/29296/25419218-2020-02-03@@Оковитый С. В., Болотова В. Ц., Анисимова Н. А. и др. Перспективы применения растительных извлечений для коррекции нарушений жирового и углеводного обмена. Фармация. 2020;69(2):17-22. https://doi.org/10/29296/25419218-2020-02-03

4. Kuche K., Bhargavi N., Dora C. P., Jain S. Drug-phospholipid complex-a go through strategy for enhanced oral bioavailability. AAPS PharmSciTech. 2019;20(2):43. https://doi.org/10.1208/s12249-018-1252-4

5. Li Z., Wang F., Liang B., et al. Methionine metabolism in chronic liver diseases: an update on molecular mechanism and therapeutic implication. Signal Transduct Target Ther. 2020;5(1):280. https://doi.org/10.1038/s41392-020-00349-7

6. Fadieienko G.D., Kushnir I. E. Efficacy of the Eslidin in patients with non-alcoholic steatohepatitis. Modern Gastroenterology. 2015;(4):32-40. (In Ukr.)@@Фадеенко Г. Д., Кушнир И. Е. Эффективность препарата «Эслидин» у больных с неалкогольным стеатогепатитом. Сучасна гастроентерологiя. 2015;(4):32-40.

7. Tkach S.M., Dorofeyev A. E. Efficacy and safety of Eslidine in patients with non-alcoholic fatty liver disease. Modern Gastroenterology. 2016;3(89):91-95. (In Russ.)@@Ткач С. М., Дорофеев А. Э. Эффективность и безопасность препарата «Эслидин» при неалкогольной жировой болезни печени. Сучасна гастроентерологiя. 2016;3(89):91-95.

8. Ivashkin V.T., Maevskaya M. V., Shirokova E. N., Morozova M. A. Global Observation of Liver Disease treatment with Eslidin®, «GOLD». RMJ. 2015;(21):1272-1277. (In Russ.)@@Ивашкин В. Т., Маевская М. В., Широкова Е. Н., Морозова М. А. Опыт применения препарата Эслидин у пациентов с неалкогольной жировой болезнью печени в практике врача амбулаторного звена (Global Observation of Liver Disease treatment with Eslidin®, «GOLD»). РМЖ. 2015;(21):1272-1277.

9. Li X., Sun R., Liu R. Natural products in licorice for the therapy of liver diseases: Progress and future opportunities. Pharmacol Res. 2019;144:210-226. https://doi.org/10.1016/j.phrs.2019.04.025

10. Selyutina O.Y., Polyakov N. E. Glycyrrhizic acid as a multifunctional drug carrier - from physicochemical properties to biomedical applications: a modern insight on the ancient drug.Int J Pharm. 2019;559:271-279. https://doi.org/10.1016/j.ijpharm.2019.01.047

11. Dajani A.I., Popovic B. Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis. World J Clin Cases. 2020;8(21):5235-5249. https://doi.org/10.12998/wjcc.v8.i21.5235

12. Yan T., Wang H., Cao L., et al. Glycyrrhizin Alleviates Nonalcoholic Steatohepatitis via Modulating Bile Acids and Meta-Inflammation. Drug Metab Dispos. 2018;46(9):1310-1319. https://doi.org/10.1124/dmd.118.082008

13. Nikitin I.G., Bajkova I. E., Kisliakov V. A., et al. Dynamics of Proinflammatory Cytokines in Patients with Alcoholic Liver Disease during Treatment with Phosphogliv. Lechebnoe Delo. 2009;(3):66-74. (In Russ.) @@Никитин И. Г., Байкова И. Е., Кисляков В. А. и др. Динамика провоспалительных цитокинов у пациентов с алкогольной болезнью печени на фоне лечения Фосфогливом. Лечебное дело. 2009;(3):66-74.

14. Mekhtiev S. N. Perspectives for complex therapy of patients with advanced fibrosis due to alcoholic liver disease. Effektivnaya Farmakoterapiya. 2011;(2):15-22. (In Russ.) @@Мехтиев С. Н. Перспективы комплексной терапии больных алкогольной болезнью печени с выраженными стадиями фиброза. Эффективная фармакотерапия. 2011;(2):15-22.

15. Li J.Y., Cao H. Y., Liu P., et al. Glycyrrhizic acid in the treatment of liver diseases: literature review. Biomed Res Int. 2014;2014:872139. https://doi.org/10.1155/2014/872139

16. Ipatova O.M., Torkhovskaia T. I., Kniazhev V. A., et al. Use of a novel hepato-protective preparation “Phosphogliv” for inhibition of development of chronic hepatitis in rats. Vopr Med Khim. 1998;44(6):537-543. (In Russ.) @@Ипатова О. М., Торховская Т. И., Княжев В. А. и др. Торможение с помощью нового гепато-протекторного препарата «Фосфоглив» развития хронического гепатита у крыс. Вопросы Медицинской Химии. 1998;44(6):537-542.

17. Ivashkin V.T., Bakulin I. G., Bogomolov P. O., et al. Efficacy and safety of glycyrrhizic acid combined to essential phospholipids (Phosphogliv) at non-alcoholic fatty liver disease: results of multicenter double blind randomized placebo-controlled post-registration clinical study (IV phase) «Gepard» (PHG-M2/P02-12).Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(2):34-43. (In Russ.) https://doi.org/10.22416/1382-4376-2017-27-2-34-43 @@Ивашкин В. Т., Бакулин И. Г., Богомолов П. О. и др. Результаты многоцентрового двойного слепого рандомизированного плацебо-контролируемого пострегистрационного (IV фаза) клинического исследования «Гепард» (PHG-M2/P02-12), проведенного с целью оценки эффективности и безопасности комбинированного препарата глицирризиновой кислоты и эссенциальных фосфолипидов (Фосфоглив) при неалкогольной жировой болезни печени. Российский Журнал Гастроэнтерологии, Гепатологии, Колопроктологии. 2017;27(2):34-43.

18. V’yuchnova Ye.S., Mayev I. V., Babina S. M. Efficacy of essential phospholipids in treatment of patients with non-alcoholic steatohepatitis. Klinicheskie Perspektivy Gastroenterologii, Gepatologii. 2010;(3):3-11. (In Russ.) @@Вьючнова Е. С., Маев И. В., Бабина С. М. Эффективность эссенциальных фосфолипидов в лечении больных с неалкогольным стеатогепатитом. Клинические перспективы гастроэнтерологии, гепатологии. 2010;(3):3-11.

19. Moyseyenko V.O., Manzhalii E. G. Possibilities of the use of Phosphogliv preparationin the treatment of steatohepatitiswith concomitant chronic colitis. Modern Gastroenterology. 2014;2(76):107-115. (In Russ.) @@Мойсеенко В. А., Манжалий Э. Г. Возможности применения препарата «Фосфоглив» в лечении стеатогепатита с сопутствующим хроническим колитом. Сучасна Гастроентерологія. 2014;2(76):107-115.

20. Bakulin I.G., Bokhan N. A., Bogomolov P. O., et al. Efficacy and safety of glycyrrhizic acid and essential phospholipids (Phosphogliv) combination for alcoholic liver disease: results of the double-blind randomized placebo-controlled multicenter post-registration (phase IV) clinical trial «Jaguar» (PHG-M2/P03-12).Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(3):57-68. (In Russ.) https://doi.org/10.22416/1382-4376-2017-27-3-57-68 @@Бакулин И. Г., Бохан Н. А., Богомолов П. О. и др. Результаты двойного слепого рандомизированного плацебо-контролируемого многоцентрового пострегистрационного (IV фаза) клинического исследования «Ягуар» (PHG-M2/P03-12) для оценки эффективности и безопасности комбинированного препарата глицирризиновой кислоты и эссенциальных фосфолипидов (Фосфоглив) при лечении больных алкогольной болезнью печени. Российский Журнал Гастроэнтерологии, Гепатологии, Колопроктологии. 2017;27(3):57-68.

21. Novikova T.I., Novikov V. S. Experience of “Phosphogliv” use for the treatment of liver injury associated with lung chemotherapy. Tuberculosis and Lung Diseases. 2011;(5):76. (In Russ.) @@Новикова Т. И., Новиков В. С. Опыт применения препарата «ФОСФОГЛИВ» в терапии поражения печени на фоне химиотерапии легких. Туберкулез и болезни легких. 2011;(5):76.

22. Shovkun L.A., Kudlay D. A., Nikolenko N. Yu. Accompanying and prevention therapy of undesirable reactions in patients with pulmonary tuberculosis. Effektivnaya farmakoterapiya. 2019;(27):12-18. (In Russ.) @@Шовкун Л. А., Кудлай Д. А., Николенко Н. Ю. и др. Терапия сопровождения и предупреждения нежелательных реакций у больных туберкулезом легких. Эффективная Фармакотерапия. 2019;(27):12-18.

23. Bayjanov A. K. Protective effciency of “Phosphogliv” at high active antiretroviral therapy in patients with HIV-infection, associated with chronic viral hepatitis C. European Sciences Review. 2016;(3-4):67-69.

24. Okada K., Shoda J., Taguchi K., et al. Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice. Am J Physiol Gastrointest Liver Physiol. 2008;295(4): G735-G747. https://doi.org/10.1152/ajpgi.90321.2008

25. Abo El-Magd N.F., El-Mesery M., El-Karef A., El-Shishtawy M. M. Glycyrrhizin ameliorates high fat diet-induced obesity in rats by activating Nrf2 pathway. Life Sci. 2018;193:159-170. https://doi.org/10.1016/j.lfs.2017.11.005

26. Amaral J.D., Viana R. J., Ramalho R. M., et al. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res. 2009;50(9):1721-1734. https://doi.org/10.1194/jlr.R900011-JLR200

27. Ko W.K., Lee S. H., Kim S. J., et al. Anti-inflammatory effects of ursodeoxycholic acid by lipopolysaccharide-stimulated inflammatory responses in RAW 264.7 macrophages. PLoS One. 2017;12(6): e0180673. https://doi.org/10.1371/journal.pone.0180673

28. Tsubota A., Kumada H., Arase Y., et al.Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients. Eur J Gastroenterol Hepatol. 1999;11(10):1077-1083.

29. Mekhtiev S.N., Mekhtieva O. A., Ibragimova Z. M. Functional gall-bladder disorders and non-alcoholic fatty liver disease: clinical features and new approaches to therapy. Medical Council. 2020;(15):54-64. (In Russ.) https://doi.org/10.21518/2079-701X-2020-15-54-64 @@Мехтиев С. Н., Мехтиева О. А., Ибрагимова З. М. Функциональные расстройства желчного пузыря и неалкогольная жировая болезнь печени: клинические особенности и новые подходы к терапии. Медицинский совет. 2020;(15):54-64. https://doi.org/10.21518/2079-701X-2020-15-54-64

30. Alyeva A.A., Nikitin I. G., Arkhipov A. V. The treatment of acute chemotherapy-induced liver injury in women with breast cancer. Lechebnoe Delo. 2018;(2):74-84. (In Russ.) @@Алыева А. А., Никитин И. Г., Архипов А. В. Сопроводительная терапия острого лекарственного повреждения печени на фоне химиотерапевтического лечения у пациенток с раком молочной железы. Лечебное дело. 2018;(2):74-84.

31. Jin J., Xiong T., Hou X., et al. Role of Nrf2 activation and NF-κB inhibition in valproic acid induced hepatotoxicity and in diammonium glycyrrhizinate induced protection in mice. Food Chem Toxicol. 2014;73:95-104. https://doi.org/10.1016/j.fct.2014.08.009

32. Vargas-Mendoza N., Morales-González Á., Morales-Martínez M., et al. Flavolignans from Silymarin as Nrf2 Bioactivators and Their Therapeutic Applications. Biomedicines. 2020;8(5):122. https://doi.org/10.3390/biomedicines8050122

33. Rasool M., Iqbal J., Malik A., et al. Hepatoprotective effects of Silybum marianum (Silymarin) and Glycyrrhiza glabra (Glycyrrhizin) in combination: a possible synergy. Evid Based Complement Alternat Med. 2014;2014:641597. https://doi.org/10.1155/2014/641597

34. Surai P. F. Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives. Antioxidants (Basel). 2015;4(1):204-247. https://doi.org/10.3390/antiox4010204

35. Tang Z.H., Li T., Chang L. L., et al. Glycyrrhetinic Acid triggers a protective autophagy by activation of extracellular regulated protein kinases in hepatocellular carcinoma cells. J Agric Food Chem. 2014;62(49):11910-11916. https://doi.org/10.1021/jf503968k

36. Liang B., Guo X. L., Jin J., et al. Glycyrrhizic acid inhibits apoptosis and fibrosis in carbon-tetrachloride-induced rat liver injury. World J Gastroenterol. 2015;21(17):5271-5280. https://doi.org/10.3748/wjg.v21.i17.5271

37. Beuers U., Trauner M., Jansen P., Poupon R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol. 2015;62(1 Suppl): S25-37. https://doi.org/10.1016/j.jhep.2015.02.023

38. Reardon J., Hussaini T., Alsahafi M., et al. Ursodeoxycholic acid in treatment of non-cholestatic liver diseases: a systematic review. J Clin Transl Hepatol. 2016;4(3):192-205. https://doi.org/10.14218/JCTH.2016.00023

39. Lazebnik L.B., Golovanova E. V., Tarasova L. V., et al. Adult Alcoholic Liver Disease. Experimental and Clinical Gastroenterology. 2020;174(2):4-28. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-174-2-4-28 @@Лазебник Л. Б., Голованова Е. В., Еремина Е. Ю. и др. Алкогольная болезнь печени (АБП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020;174(2):4-28. https://doi.org/10.31146/1682-8658-ecg-174-2-4-28

40. Lazebnik L.B., Golovanova E. V., Turkina S. V., et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4-52. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-185-1-4-52 @@Лазебник Л. Б., Голованова Е. В., Туркина С. В. и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;1(1):4-52. https://doi.org/10.31146/1682-8658-ecg-185-1-4-52

41. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-402. https://doi.org/10.1016/j.jhep.2015.11.004

42. Chalasani N., Younossi Z., Lavine J. E., et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. https://doi.org/10.1002/hep.29367

43. Perumpail B.J., Li A. A., John N., et al. The Role of Vitamin E in the Treatment of NAFLD. Diseases. 2018;6(4):86. Published 2018 Sep 24. https://doi.org/10.3390/diseases6040086

44. Amaral J.D., Castro R. E., Solá S., Steer C. J., Rodrigues C. M. p53 is a key molecular target of ursodeoxycholic acid in regulating apoptosis. J Biol Chem. 2007;282(47):34250-34259. https://doi.org/10.1074/jbc.M704075200

45. Tsagarakis N.J., Drygiannakis I., Batistakis A. G., et al. A concentration-dependent effect of ursodeoxycholate on apoptosis and caspases activities of HepG2 hepatocellular carcinoma cells. Eur J Pharmacol. 2010;640(1-3):1-7. https://doi.org/10.1016/j.ejphar.2010.04.023

46. Rodrigues C.M., Fan G., Wong P. Y., et al. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med. 1998;4(3):165-178.

47. Balmer M.L., Siegrist K., Zimmermann A., Dufour J. F. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int. 2009;29(8):1184-1188. https://doi.org/10.1111/j.1478-3231.2009.02037.x

48. Dufour J.F., Oneta C. M., Gonvers J. J., et al. Randomized.placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2006;4(12):1537-43. https://doi.org/10.1016/j.cgh.2006.09.025

49. Pietu F., Guillaud O., Walter T., et al. Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: long-term results. Clin Res Hepatol Gastroenterol. 2012;36(2):146-155. https://doi.org/10.1016/j.clinre.2011.10.011

50. Bordbar M., Shakibazad N., Fattahi M., et al. Effect of ursodeoxycholic acid and vitamin E in the prevention of liver injury from methotrexate in pediatric leukemia. Turk J Gastroenterol. 2018;29(2):203-209. https://doi.org/10.5152/tjg.2018.17521

51. Castro R.E., Ferreira D. M., Afonso M. B., et al. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol. 2013;58(1):119-125. https://doi.org/10.1016/j.jhep.2012.08.008

52. Katiyar S.K., Roy A. M., Baliga M. S. Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome c release, and caspase activation. Mol Cancer Ther. 2005;4(2):207-216.

53. Alaca N., Ozbeyli D., Uslu S., et al. Treatment with milk thistle extract (Silybum marianum), ursodeoxycholic acid, or their combination attenuates cholestatic liver injury in rats: role of the hepatic stem cells. Turk J Gastroenterol. 2017;28(6):476-484. https://doi.org/10.5152/tjg.2017.16742

54. Bettini R., Gorini M. Use of ursodeoxycholic acid combined with silymarin in the treatment of chronic ethyl-toxic hepatopathy. Clin Ter. 2002;153(5):305-307.

55. Chamulitrat W., Zhang W., Xu W., et al. Hepatoprotectant ursodeoxycholyl lysophosphatidylethanolamide increasing phosphatidylcholine levels as a potential therapy of acute liver injury. Front Physiol. 2012;3:24. https://doi.org/10.3389/fphys.2012.00024

56. Pathil A., Liebisch G., Okun J. G., et al. Ursodeoxycholyl lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD. Eur J Clin Invest. 2015;45(9):925-931. https://doi.org/10.1111/eci.12486

57. Su J., Gan-Schreier H., Goeppert B., et al. Bivalent ligand UDCA-LPE inhibits pro-fibrogenic integrin signalling by inducing lipid raft-mediated internalization.Int J Mol Sci. 2018; 19(10): E3254. https://doi.org/10.3390/ijms19103254

58. Marciniak B., Kimber-Trojnar Z., Leszczynska-Gorzelak B., et al. Treatment of obstetric cholestasis with polyunsaturated phosphatidylcholine and ursodeoxycholic acid. Ginekol Pol. 2011;82(1):26-31.

59. Mato J.M., Lu S. C. Role of S-adenosyl-L-methionine in liver health and injury. Hepatology. 2007;45(5):1306-1312. https://doi.org/10.1002/hep.21650

60. Lu S.C., Mato J. M. S-Adenosylmethionine in cell growth, apoptosis and liver cancer. J Gastroenterol Hepatol. 2008;23(Suppl 1): S73-S77. https://doi.org/10.1111/j.1440-1746.2007.05289.x

61. Nicastri P.L., Diaferia A., Tartagni M., et al. A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. Br J Obstet Gynaecol. 1998;105(11):1205-1207.

62. Binder T., Salaj P., Zima T., Vítek L. Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. J Perinat Med. 2006;34(5):383-391. https://doi.org/10.1515/JPM.2006.077

63. Zhang L., Liu X. H., Qi H. B., et al. Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. Eur Rev Med Pharmacol Sci. 2015;19(19):3770-3776.

64. Zhou F., Gao B., Wang X., Li J. Meta-analysis of ursodeoxycholic acid and S-adenosylmethionine for improving the outcomes of intrahepatic cholestasis of pregnancy. Chinese Journal of Hepatology. 2014;22(4):299-304. https://doi.org/10.3760/cma.j.issn.1007-3418.2014.04.013

65. Zhang Y., Lu L., Victor D. W., et al. Ursodeoxycholic acid and S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy: a meta-analysis. Hepat Mon. 2016;16(8): e38558. https://doi.org/10.5812/hepatmon.38558

66. Russian Society of Obstetricians and Gynaecologists.Intrahepatic cholestasis in pregnancy: clinical guidelines. Moscow; 2019. Российское общество акушеров-гинекологов (РОАГ). Внутрипеченочный холестаз при беременности: клинические рекомендации. Москва; 2019.

67. Wunsch E., Raszeja-Wyszomirska J., Barbier O., et al. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study. J Gastrointestin Liver Dis. 2018;27(3):273-279. https://doi.org/10.15403/jgld.2014.1121.273.icz

68. Podymova S.D., Nadinskaia M. Yu. Clinical trial of Heptral in patients with chronic diffuse liver disease withintrahepatic cholestasis syndrome. Klinicheskaia Meditsina. 1998;76(10):45-8 (In Russ.) @@Подымова С. Д., Надинская М. Ю. Оценка эффективности препарата Гептрал у больных хроническими диффузными заболеваниями печени с синдромом внутрипеченочного холестаза. Клиническая медицина. 1998;76(10):45-8.

69. Raykhel’son K.L., Mitel’glik U.A., Zubareva A. S., et al. Principles and perspectives of primary biliary cirrhosis therapy. Experimental and Clinical Gastroenterology. 2012;(3):90-5 (In Russ.)@@ Райхельсон К. Л., Мительглик У. А., Зубарева А. С. и др. Принципы и перспективы лечения первичного билиарного цирроза. Экспериментальная и клиническая гастроэнтерология. 2012;(3):90-5.

70. Avezov S.A., Mansurova F. Kh. Efficacy of combined administration of ursodeoxycholic acid and Heptral in the treatment of primary biliary cirrhosis. Klinicheskaia Meditsina. 2004;82(2):46-50. (In Russ.) @@Авезов С. А., Мансурова Ф. Х. Эффективность комбинированного применения урсодеоксихолевой кислоты и гептрала в лечении первичного билиарного цирроза. Клиническая медицина. 2004;82(2):46-50.

71. Larionova V.B., Gromova E. G., Snegovoy A. V. Clinical guidelines on the correction of hepatotoxicity induced by antineoplastic chemotherapy. Moscow; 2014. @@Ларионова В. Б., Громова Е. Г., Снеговой А. В. Клинические рекомендации по коррекции гепатотоксичности, индуцированной противоопухолевой химиотерапией. Москва; 2014.

72. Salehi B., Berkay Yılmaz Y., Antika G., et al. Insights on the Use of α-Lipoic Acid for Therapeutic Purposes. Biomolecules. 2019;9(8):356. Published 2019 Aug 9. https://doi.org/10.3390/biom9080356

73. Kiemer A.K., Müller C., Vollmar A. M. Inhibition of LPS-induced nitric oxide and TNF-alpha production by alpha-lipoic acid in rat Kupffer cells and in RAW 264.7 murine macrophages. Immunol Cell Biol. 2002;80(6):550-557. https://doi.org/10.1046/j.1440-1711.2002.01124.x

74. Liu G., Liu J., Pian L., Gui S., Lu B. α-lipoic acid protects against carbon tetrachloride-induced liver cirrhosis through the suppression of the TGF-β/Smad3 pathway and autophagy. Mol Med Rep. 2019;19(2):841-850. https://doi.org/10.3892/mmr.2018.9719

75. Gianturco V., Troisi G., Bellomo A., et al. Impact of combined therapy with alpha-lipoic and ursodeoxycolic acid on nonalcoholic fatty liver disease: double-blind, randomized clinical trial of efficacy and safety. Hepatol Int. 2013;7(2):570-576. https://doi.org/10.1007/s12072-012-9387-y

76. Li C.C., Hsiang C. Y., Wu S. L., Ho T. Y. Identification of novel mechanisms of silymarin on the carbon tetrachloride-induced liver fibrosis in mice by nuclear factor-κB bioluminescent imaging-guided transcriptomic analysis. Food Chem Toxicol. 2012;50(5):1568-1575. https://doi.org/10.1016/j.fct.2012.02.025

77. Aller R., Izaola O., Gomez S., et al. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study. Eur Rev Med Pharmacol Sci. 2015;19(16):3118-3124.

78. Sorrentino G., Crispino P., Coppola D., De Stefano G. Efficacy of lifestyle changes in subjects with non-alcoholic liver steatosis and metabolic syndrome may be improved with an antioxidant nutraceutical: a controlled clinical study. Drugs R D. 2015;15(1):21-25. https://doi.org/10.1007/s40268-015-0084-x

79. Serviddio G., Bellanti F., Giudetti A. M., et al. A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. J Pharmacol Exp Ther. 2010;332(3):922-32. https://doi.org/10.1124/jpet.109.161612

80. Federico A., Dallio M., Di Fabio G., et al. Silybin-Phosphatidylcholine complex protects human gastric and liver cells from oxidative stress. In Vivo. 2015;29(5):569-575.

81. Sun S.S., Wu Y. X., Cheng M. L., et al. Experimental study of silybin-phospholipid complex intervention on amiodarone-induced fatty liver in mice. Chin J Hepatol. 2019;27(1):45-50. https://doi.org/10.3760/cma.j.issn.1007-3418.2019.01.010

82. Khadzhieva B. R.Comparative efficacy of different silymarin preparations in course therapy of alcoholic liver disease. Abstr. cand. diss. … med. sciences. Moscow; 2009. (In Russ.) @@Хаджиева Б. Р. Сравнительная эффективность различных лекарственных препаратов силимарина в курсовой терапии алкогольной болезни печени. Автореф. канд. дисс. … мед. наук. Москва, РФ; 2009.

83. Di Sario A., Bendia E., Taffetani S., et al. Hepatoprotective and antifibrotic effect of a new silybin- phosphatidylcholine- Vitamin E complex in rats. Dig Liver Dis. 2005;37(11):869-876. https://doi.org/10.1016/j.dld.2005.05.011

84. Grattagliano I., Diogo C. V., Mastrodonato M., et al. A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes. World J Gastroenterol. 2013;19(20):3007-3017. https://doi.org/10.3748/wjg.v19.i20.3007

85. Abenavoli L., Greco M., Nazionale I., et al. Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9(4):519-527. https://doi.org/10.1586/17474124.2015.1004312

86. Loguercio C., Andreone P., Brisc C., et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic Biol Med. 2012;52(9):1658-1665. https://doi.org/10.1016/j.freeradbiomed.2012.02.008

87. Federico A., Trappoliere M., Tuccillo C., et al. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut. 2006;55(6):901-902. https://doi.org/10.1136/gut.2006.091967

88. Derakhshandeh-Rishehri S.M., Heidari-Beni M., Eftekhari M. H. The effects of Realsil (silybin-phospholipid-vitamin e complex) on liver enzymes in patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steato-hepatitis (NASH): a systematic review and meta-analysis of RCTs. Acta Endocrinol (Buchar). 2020;16(2):223-231. https://doi.org/10.4183/aeb.2020.223

89. Malaguarnera M., Motta M., Vacante M., et al. Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin. Am J Transl Res. 2015;7(11):2510-2518.

90. Falasca K., Ucciferri C., Mancino P., et al. Treatment with silybin-vitamin E-phospholipid complex in patients with hepatitis C infection. J Med Virol. 2008;80(11):1900-1906. https://doi.org/10.1002/jmv.21292

91. Sanchez-Niño M.D., Bozic M., Córdoba-Lanús E., et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol. 2012;302(6): F647-F657. https://doi.org/10.1152/ajprenal.00090.2011

92. Liu W., Zhang L., Xu H. J., et al. The Anti-Inflammatory Effects of Vitamin D in Tumorigenesis.Int J Mol Sci. 2018;19(9):2736. https://doi.org/10.3390/ijms19092736

93. Helming L., Böse J., Ehrchen J., et al. 1alpha,25-Dihydroxyvitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation. Blood. 2005;106(13):4351-4358. https://doi.org/10.1182/blood-2005-03-1029

94. Iruzubieta P., Terán Á., Crespo J., Fábrega E. Vitamin D deficiency in chronic liver disease. World J Hepatol. 2014;6(12):901-915. https://doi.org/10.4254/wjh.v6.i12.901

95. Federico A., Dallio M., Masarone M., et al. Evaluation of the effect derived from silybin with vitamin D and vitamin E administration on clinical, metabolic, endothelial dysfunction, oxidative stress parameters, and serological worsening markers in nonalcoholic fatty liver disease patients. Oxid Med Cell Longev. 2019;2019:8742075. https://doi.org/10.1155/2019/8742075

96. Au A.Y., Hasenwinkel J. M., Frondoza C. G. Hepatoprotective effects.of S-adenosylmethionine and silybin on canine hepatocytes in vitro. J Anim Physiol Anim Nutr. 2013;97(2):331-341. https://doi.org/10.1111/j.1439-0396.2012.01275.x

97. Giangrandi I., Dinu M., Pagliai G., et al. Efficacy of oral supplementation with silymarin and s-adenosyl-l-methionine in patients with non-alcoholic fatty liver disease - a pilot study. Altern Integr Med. 2016;5(4):224. https://doi.org/10.4172/2327-5162.1000224

98. Ellulu M.S., Rahmat A., Patimah I., et al. Effect of vitamin C on inflammation and metabolic markers in hypertensive and/or diabetic obese adults: a randomized controlled trial. Drug Des Devel Ther. 2015;9:3405-3412. https://doi.org/10.2147/DDDT.S83144

99. Abdulrazzaq A.M., Badr M., Gammoh O., et al. Hepatoprotective actions of ascorbic acid, alpha lipoic acid and silymarin or their combination against acetaminophen-induced hepatotoxicity in rats. Medicina (Kaunas). 2019;55(5): E181. https://doi.org/10.3390/medicina55050181

100. Yuan Q., Xin L., Han S., et al. Lactulose Improves Neurological Outcomes by Repressing Harmful Bacteria and Regulating Inflammatory Reactions in Mice After Stroke. Front Cell Infect Microbiol. 2021;11:644448. https://doi.org/10.3389/fcimb.2021.644448

101. Taskin B., Erdoğan M. A., Yiğittürk G., et al. Antifibrotic Effect of Lactulose on a Methotrexate-Induced Liver Injury Model. Gastroenterol Res Pract. 2017;2017:7942531. https://doi.org/10.1155/2017/7942531

102. Ghobadi Pour M., Mirazi N., Alaei H., et al. Effects of lactulose and silymarin on liver enzymes in cirrhotic rats. Can J Physiol Pharmacol. 2017;95(5):522-529. https://doi.org/10.1139/cjpp-2016-0454

103. Ghobadi Pour M., Mirazi N., Alaei H., et al. The effects of concurrent treatment of silymarin and lactulose on memory changes in cirrhotic male rats. Bioimpacts. 2020;10(3):177-186. https://doi.org/10.34172/bi.2020.22

104. Jantararussamee C., Rodniem S., Taweechotipatr M., et al. Hepatoprotective Effect of Probiotic Lactic Acid Bacteria on Thioacetamide-Induced Liver Fibrosis in Rats. Probiotics Antimicrob Proteins. 2021;13(1):40-50. https://doi.org/10.1007/s12602-020-09663-6

105. Emam M.A., Farouk S. M., Abdo M. the ameliorative potential of probiotics and/or silymarin on thioacetamide induced hepatotoxicity in rats: histological and immunohistochemical study.Int J Morphol. 2018;36(2):661-669.

106. Prikhodko V.A., Bezborodkina N. N., Okovityi S. V. Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates. Biomedicines. 2022;10(2):274. https://doi.org/10.3390/biomedicines10020274

107. Poruba M., Anzenbacher P., Racova Z., et al. The effect of combined diet containing n-3 polyunsaturated fatty acids and silymarin on metabolic syndrome in rats. Physiol Res. 2019;68(Suppl 1): S39-S50.

108. Wei H.L., Liu G. T. [Protective action of corynoline, acetylcorynoline and protopine against experimental liver injury in mice]. Yao Xue Xue Bao. 1997;32(5):331-336.

109. Gupta RK, Swain SR, Sahoo J, et al. Isolation, characterization and hepatoprotective activity of naturally occurring protopine against simvastatin induced liver toxicity in experimental rodents. Curr Bioact Comp. 2020;16(5):568-575. https://doi.org/10.2174/1573407215666190211151306

110. Xiao L., Zeng J., Liu L., et al. Effect of allocryptopine on antagonizing hepatic fibrosis. Chinese Traditional and Herbal Drugs. 2011;42(6):1158-1163.

111. Sharma U.R., Prakash T., Surendra V., et al. Hepatoprotective activity of Fumaria officinalis against CCl4-induced liver damage in rats. Pharmacologiia. 2012;3(1):9-14.

112. Hepabene. Registration certificate P N012369/01. State Register of Medicines of the Russian Federation. (In Russ.) @@Гепабене. Регистрационное удостоверение П N012369/01. Государственный реестр лекарственных средств РФ.

113. Burkov S.G., AT Arutyunov, Yegorova N. V., et al. Efficacy of drug Hepabene in the treatment of fatty liver disease. Farmateka. 2010;(15):87-92. (In Russ.) @@Бурков С. Г., Арутюнов А. Т., Егорова Н. В. и др. Эффективность препарата Гепабене в лечении жировой болезни печени. Фарматека. 2010;(15):87-92.

114. Vyuchnova E.S., Maev I. V., Babina S. M. Experience of use of Hepabene in the treatment of non-alcoholic steatohepatitis. Farmateka. 2010;(12):76-81. (In Russ.) @@Вьючнова Е. С., Маев И. В., Бабина С. М. Опыт использования Гепабене в лечении неалкогольного стеатогепатита. Фарматека. 2010;(12):76-81.

115. Mahmoodzadeh Y., Mazani M., Rezagholizadeh L. Hepatoprotective effect of methanolic Tanacetum parthenium extract on CCl4-induced liver damage in rats. Toxicol Rep. 2017;4:455-462. https://doi.org/10.1016/j.toxrep.2017.08.003

116. Popović M., Jakovljević M., Mimica-Dukić N., et al. Effects of different extracts of Hypericum perforatum L. on the CCl4-induced hepatotoxicity in rats. Oxid Commun. 2002;25:273-278.

117. Hohmann M.S., Cardoso R. D., Fattori V., et al. Hypericum perforatum Reduces Paracetamol-Induced Hepatotoxicity and Lethality in Mice by Modulating Inflammation and Oxidative Stress. Phytother Res. 2015;29(7):1097-1101. https://doi.org/10.1002/ptr.5350

118. Abd El-Hameed A.M., Eskandrani A. A., Elroby F. A. Assessment of the ameliorative effect of Hypericum perforatum on olanzapine-induced hepatic oxidative stress and metabolic abnormalities in experimental male albino rats. J Taibah Univ Sci. 2020;14(1):1496-1502. https://doi.org/10.1080/16583655.2020.1834757

119. Bayramoglu G., Bayramoglu A., Engur S., et al. The hepatoprotective effects of Hypericum perforatum L. on hepatic ischemia/reperfusion injury in rats. Cytotechnology. 2014;66(3):443-448. https://doi.org/10.1007/s10616-013-9595-x

120. Abdel-Salam O., Sleem A., Shaffie N. M. Hypericum perforatum protects against hepatic injury induced by carbon tetrachloride.Comparative Clinical Pathology. 2011;21:1149-1157. https://doi.org/10.1007/s00580-011-1252-1

121. Bai T., Yang Y., Yao Y. L., et al. Betulin alleviated ethanol-induced alcoholic liver injury via SIRT1/AMPK signaling pathway. Pharmacol Res. 2016;105:1-12. https://doi.org/10.1016/j.phrs.2015.12.022

122. Yi J., Xia W., Wu J., et al. Betulinic acid prevents alcohol-induced liver damage by improving the antioxidant system in mice. J Vet Sci. 2014;15(1):141-148. https://doi.org/10.4142/jvs.2014.15.1.141

123. Ji S.J., Kim J. H. Protective effects of Betula platyphylla var. japonica extracts against the cellular damage induced by reactive oxygen species.Int J Oral Biol. 2009;34(1):15-20.

124. Lee M., Park J. H., Min D. S., et al. Antifibrotic activity of diarylheptanoids from Betula platyphylla toward HSC-T6 cells. Biosci Biotechnol Biochem. 2012;76(9):1616-1620. https://doi.org/10.1271/bbb.110887

125. Karabaeva V.V., Vichkanova S. A., Sidelnikova G. F., et al. The use of Sebektan in the treatment of chronic cholecystitis. Problems of Biological, Medical and Pharmaceutical Chemistry. 2016;(3):16-20. (In Russ.) @@Карабаева В. В., Вичканова С. А., Сидельникова Г. Ф. и др. Применение сибектана в терапии хронического холецистита. Вопросы биологической, медицинской и фармацевтической химии. 2016;(3):16-20.

126. Maximov M.L., Shindina T. S., Kropova O. E. Hepatoprotective and infusion therapy in patients with inflammatory liver diseases. RMJ. Medical Review. 2018;2(7(II)):82-87. (In Russ.) @@Максимов М. Л., Шиндина Т. С., Кропова О. Е. Гепатопротекторная и инфузионная терапия пациентов с воспалительными заболеваниями печени. РМЖ. Медицинское обозрение. 2018;2(7(II)):82-87.

127. Guo W., Xiang Q., Mao B., et al. Protective Effects of Microbiome-Derived Inosine on Lipopolysaccharide-Induced Acute Liver Damage and Inflammation in Mice via Mediating the TLR4/NF-κB Pathway. J Agric Food Chem. 2021;69(27):7619-7628. https://doi.org/10.1021/acs.jafc.1c01781

128. Wang S., Wan T., Ye M., et al. Nicotinamide riboside attenuates alcohol induced liver injuries via activation of SirT1/PGC-1α/mitochondrial biosynthesis pathway. Redox Biol. 2018;17:89-98. https://doi.org/10.1016/j.redox.2018.04.006

129. Ilchenko L. Yu., Okovity S. V. Remaxol: mechanisms of action and application in real clinical practice. Part I. The Russian Archives of Internal Medicine. 2016;6(2):16-21. (In Russ.) @@Ильченко Л. Ю., Оковитый С. В. Ремаксол: механизмы действия и применение в клинической практике. Часть 1. Архивъ внутренней медицины. 2016;6(2):16-21.

130. Ilchenko L. Yu., Okovity S. V. Remaxol: mechanisms of action and application in real clinical practice. Part II. The Russian Archives of Internal Medicine. 2016;6(3):8-18. (In Russ.)@@ Ильченко Л. Ю., Оковитый С. В. Ремаксол: механизмы действия и применение в клинической практике. Часть 2. Архивъ внутренней медицины. 2016;6(3):8-18.

131. Okovityi S.V., Pad'ko S. V. Mitochondrial dysfunction’s role in pathogenesis of different liver disorders. Doctor.Ru. 2015;12:30-33. (In Russ.) @@Оковитый С. В., Радько С. В. Митохондриальная дисфункция в патогенезе различных поражений печени. Доктор.Ру. 2015;12:30-33.

132. Okovityi S.V., Prikhodko V. A., Bezborodkina N. N., Kudryavtsev B. N. Hepatoprotectors. Moscow; 2022. (In Russ.) @@Оковитый С. В., Приходько В. А., Безбородкина Н. Н., Кудрявцев Б. Н. Гепатопротекторы. Москва; 2022.

133. Shannon P., Markiel A., Ozier O., et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-2504. https://doi.org/10.1101/gr.1239303

134. Summer G., Kelder T., Ono K., et al. cyNeo4j: connecting Neo4j and Cytoscape. Bioinformatics. 2015;31(23):3868-3869. https://doi.org/10.1093/bioinformatics/btv460